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Inhaled glucocorticosteroids such as budesonide have an important role in the management of asthma. Although 
these agents have traditionally been given twice daily, evidence is accumulating that once-daily treatment may be as 
effective as twice-daily administration. The efficacy of budesonide Turbuhale@ (Astra, Lund, Sweden), 400,ug once 
daily in the evening or 200 ,ug twice daily, was compared in a randomized, double-blind study involving 181 patients 
(75 men, 106 women; mean age 30.8 years) with mild asthma [mean forced expiratory volume in 1 s (FEV,) 92.8% 
pred.] who had not previously been treated with inhaled glucocorticosteroids. After a 2-week run-in period, patients 
were randomized to either regimen and treated for 6 weeks. This was followed by two 8-week open treatment 
periods, during which all patients received budesonide Turbuhaler @, 2OOpg once daily during the first period and 
100 pug once daily during the second period. The mean change in morning peak expiratory flow (PEF) during the 
double-blind treatment period was 16.9 1 min - ’ in patients receiving once-daily treatment and 17.2 1 min - i in those 
receiving twice-daily treatment. Similarly, there were no significant differences in evening PEF, symptom scores, 
bronchodilator use or spirometry data between patients receiving once- and twice-daily treatments. The improve- 
ments in morning PEF, symptom scores and bronchodilator use seen during the double-blind treatment period were 
maintained during the two open treatment periods. It is concluded that once-daily treatment with budesonide 
Turbuhaler@ is as effective as an initial therapy twice-daily treatment in patients with mild persistent asthma, and 
that the initial dose can be reduced to maintenance levels (including 100 pug) without loss of asthma control. 
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Introduction 
Since the recognition of asthma as primarily an in- 
flammatory disease (1) inhaled glucocorticosteroids 
(iGCS) such as budesonide have taken a leading role in its 
management. In clinical trials, iGCS have been shown to 
improve lung function and symptom scores (24), and to 
reduce bronchial reactivity and asthma exacerbations 
(2,4). As a result, the use of iGCS has expanded beyond 
their original role as a substitute for oral steroid 
therapy, and these agents are now increasingly accepted 
as first-line therapy in patients with newly diagnosed 
asthma (5,6). 
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In most patients, asthma can be well controlled by 
twice-daily dosing with iGCS, although treatment can be 
given up to four times daily in patients with severe asthma 
(7). Recent studies, however, have suggested that once-daily 
dosing with budesonide, delivered via Turbuhaler@, is as 
effective as twice-daily dosing in patients with mild to 
moderate asthma (8). Once-daily treatment might be 
expected to offer advantages in terms of simplicity and 
convenience to the patient, and hence potentially enhanced 
compliance. 
The present study was performed to compare the efficacy 
of once- and twice-daily administration of budesonide via 
Turbuhaler@ in patients with mild to moderate asthma who 
had not previously been treated with iGCS. Since current 
guidelines for the management of asthma recommend 
titrating the initial dose down to the lowest dose required to 
maintain asthma control, a secondary objective was to 
determine the minimum maintenance dose that could be 
given once-daily. 
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Methods ASSESSMENTS 
Demographic characteristics and a medical history were 
recorded at the start of the run-in period, and patients were 
given a Vitalograph (Astra, Ireland) peak flow meter and a 
diary card to record peak flow values, bronchodilator use, 
symptoms and use of study drug. PEF was measured 
each morning and evening throughout the study; on each 
occasion, the highest of three measurements was recorded 
in the diary. All measurements were made before admin- 
istration of any rescue &agonist. Day- and night-time 
symptom scores were recorded separately. Cough, wheeze 
and breathlessness were scored on a seven-point scale, 
which ranged from 0 (no symptoms) to 6 (virtually unbear- 
able symptoms; the greatest discomfort or distress ever 
experienced). 
PEF, the forced expiratory volume in 1 s (FEV,) and 
forced vital capacity (FVC) were measured by spirometry 
during clinic visits at the start of the run-in period, at the 
start of drug treatment, and after 6,10, 14, 18 and 22 weeks 
of treatment. All measurements in each patient were per- 
formed at approximately the same time of day, and were 
performed with the patient seated and wearing a nose-clip; 
patients were instructed not to lean forwards during 
exhalation, and were informed that the exhalation should 
preferably continue for more than 6 s. The spirometer was 
calibrated before use by each new patient. The highest 
FEV, and FVC values from three satisfactory exhalations 
should not exceed the next highest values by more than 5% 
or 100 ml, whichever was the greater. The highest PEF 
value from three satisfactory exhalations was recorded. 
European Community reference values for PEF, FEV, and 
FVC were used (10). 
Patients’ PEF measurements and inhaler technique were 
checked at each clinic visit. Information about adverse 
events during drug treatment was obtained from spon- 
taneous reports and from the patients’ response to a 
standard question, “Have you had any health problems or 
symptoms not usually associated with your asthma since 
your last visit?“. 
The numbers of patients with stable asthma in each 
group were compared at 6, 14 and 22 weeks. Asthma was 
regarded as stable if the following criteria were met: mean 
PEF during the 10 days before clinic visit, and/or FEV,, at 
least 80% of predicted; no increase in daytime asthma 
symptoms compared with the baseline mean, and no 
nocturnal symptoms, during the 10 days before clinic visit; 
mean use of inhaled &-agonist during the 10 days before 
clinic visit equal to or lower than that at baseline. 
STUDY DESIGN 
The study was a parallel-group trial conducted at five 
centres in Hungary and six centres in Spain. After a 2-week 
run-in period, eligible patients were randomized to receive 
budesonide Turbuhaler@, 400 ,ug once daily in the evening 
or 200,ug twice daily, for 6 weeks. The double-blind 
treatment period was followed by two open treatment 
periods, during which all patients received budesonide 
Turbuhaler@, 2OOpg once daily in the evening, for 8 
weeks, followed by 100,~g once daily in the evening for 
8 weeks. 
The study was performed according to the principles of 
the Declaration of Helsinki, and approved by local ethics 
committees. 
PATIENTS 
A total of 183 patients, aged 17-67 years (mean 30.8 
years), with bronchial asthma as defined by the American 
Thoracic Society criteria (9) took part in the study. All 
had a peak expiratory flow (PEF) of at least 70% of 
predicted normal value at least 6 h after the last use of an 
inhaled &agonist, together with at least 15% variation 
in PEF (the difference between the highest and lowest 
recorded values), during the last 6 days of the run-in 
period, or showed asthma symptoms and used inhaled 
j&-agonist on at least three of the last 6 days of the run-in 
period. Patients were required to demonstrate that they 
were competent in using Turbuhaler@ and a peak flow 
meter. Patients who had received iGCS therapy within 3 
months of enrolment, or other glucocorticosteroid therapy 
or cromoglycate within the previous 2 months, were 
excluded, as were patients who had experienced asthma 
exacerbations within the preceding 2 months or respirat- 
ory infections within the preceding 4 weeks. Written or 
witnessed verbal informed consent was obtained from all 
patients before enrolment. 
TREATMEMT 
Budesonide treatment was given by Turbuhaler@. Morning 
and evening doses were to be taken at the same times each 
day, preferably at 12-hour intervals. During the double- 
blind phase, patients randomized to once-daily treatment 
received identical placebo inhalers to be used in the 
morning; inhalers intended for morning and evening use 
were colour-coded. All patients received terbutaline sul- 
phate (Bricanyl Turbuhaler” or pressurized metered 
dose inhaler, 250 pg dose - ‘) for use as rescue medication. 
Other &agonists, theophyllines, disodium cromoglycate, 
nedocromil sodium or glucocorticosteroids other than 
study medication, were not permitted during the study. 
Non-asthma medication (except for beta-blockers) con- 
sidered necessary for the patient’s welfare could be given at 
the discretion of the investigator. 
The technical usage of the Turbuhaler was checked by 
the study nurse. 
STATISTICAL ANALYSIS 
It was calculated that with 85 patients in each treatment 
group, the study would have an 80% chance of detecting a 
221min’ difference between the two groups in the change 
in morning PEF. This was based on experience from 
previous studies, in which the standard deviation of the 
change in PEF was approximately 50 1 min- ‘. 
The primary statistical analysis was an intention-to-treat 
analysis, which included all randomized patients. The 
principal efficacy variable was morning PEF, measured by 
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TABLE 1. Patient demographic characteristics and asthma history. Data are presented as means and 
ranges 
Budesonide, 400 ,ug Budesonide, 200 ,ug 
once daily twice daily 
(n=90) (n=91) 
Men/women 
Age (years) 
Height (cm) 
Weight (kg) 
Duration of asthma (months) 
Time since last exacerbation (months) 
42148 33158 
30.1 (17G58.0) 31.5 (17G-67~0) 
169.4 (147X)-195.0) 167.2 (146G188.0) 
71.6 (43@-110.0) 69.9 (45.0-l 11.0) 
80.6 (O&407.8) 91.5 (OG419.9) 
12.5 (0.1-166.1) 13.0 (0.1-138.9) 
TABLE 2. Lung function and symptom scores at baseline. Data are presented as means and ranges 
Once-daily treatment Twice-daily treatment 
Diary variables 
Morning PEF (1 min - ‘) 
Evening PEF (1 min - ‘) 
Cough (daytime) 
Cough (night-time) 
Wheeze (daytime) 
Wheeze (night-time) 
Breathlessness (daytime) 
Breathlessness (night-time) 
&agonist use (puffs day - ‘) 
&agonist use (puffs night - ‘) 
Clinic assessments 
PEF (1 min - ‘) 
FEV, (1) 
FEV, (% of predicted) 
FVC (1) 
FVC (% of predicted) 
419 (187-750) 416 (194782) 
425 (199-758) 427 (201-704) 
0.87 (0.0-3.60) 1.03 (OG-5.40) 
0.70 (0.0-3.40) 0.87 (OG4.90) 
0.54 (0.0-2.60) 0.56 (OG3.25) 
0.49 (0.0-2.60) 0.56 (0.0-3.70) 
0.76 (0.0-2.50) 1.04 (0.04.80) 
0.65 (0.0-2.60) 0.98 (0.04.30) 
0.94 (0.04.80) 1.17 (0.0-7.60) 
0.66 (0.0-3.20) 0.77 (OG4.60) 
469 (252-882) 467 (101-882) 
3.31 (164-5.40) 3.14 (0.984.92) 
92.9 (65.2-132.8) 92.7 (44.5-135.2) 
4.20 (2.29-6.46) 3.97 (1.67-6.32) 
100.7 (67.5-140.0) 100.3 (644-143.5) 
peak flow meter. The mean values over the 10 days before 
each clinic visit were calculated for each patient and used 
for statistical analysis. Secondary variables were diary 
records of symptom scores and bronchodilator use, and 
spirometry data. For diary variables, the mean values 
during the 10 days before each clinic visit were used for 
analysis. Changes from baseline were analysed by analysis 
of variance (ANOVA), with factors for treatment and 
centre. The primary endpoint was the change from baseline 
to the end of the double-blind treatment period; baseline 
values were used as covariates in the analyses. For clinic 
and diary data, missing values were replaced according to 
the last-observation-carried-forward principle. 
Results 
Of the 183 randomized patients, two (one in each group) 
were not treated and hence were excluded from all analyses. 
Of the remaining patients, 90 were randomized to receive 
once daily budesonide, and 91 to twice-daily treatment. The 
demographic characteristics and asthma history of these 
patients, with baseline lung function data and symptom 
scores, are summarized in Tables 1 and 2. The mean FEV, 
(% of predicted) was similar in the two treatment groups, 
while symptom scores were slightly higher in patients 
receiving twice-daily treatment. However, these differences 
were not considered clinically relevant. 
A total of 50 patients (25 in each group) withdrew 
during the course of the study. Of these, 27 (16 in the 
once-daily group and 11 in the twice-daily group) with- 
drew during the double-blind treatment period; two (one 
in each group) withdrew because of adverse events and 
two (one in each group) because of asthma deterioration. 
The remaining 23 (nine in the once-daily group; 14 in the 
twice-daily group) withdrew during the open follow-up 
period; one patient receiving once-daily treatment because 
of adverse effects, and eight (two in the once-daily group 
and six in the twice-daily group) because of deterioration 
of asthma. 
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FIG. 1. Mean morning PEF values during the run-in 
period and double-blind treatment with budesonide, 
400 pg once daily (- +- -) or 2OOpg twice daily (a-). 
EFFICACY 
The mean change in morning PEF from baseline (the mean 
value during the last 10 days of the run-in period) to the 
last 10 days of the double-blind treatment period was 
16,91min-’ in patients receiving once-daily treatment 
and 17.2 1 min - ’ in those receiving twice-daily treatment 
(Fig. 1). The mean difference between the groups 
was - 0.3 1 min - ’ (95% confidence limits: - 14.8, 
+ 14.2 1 min - ‘), which was not statistically significant. 
Similar results were obtained in an analysis of morning 
PEF as a percentage of predicted values, which was carried 
out to check the sensitivity of the PEF analysis in view of a 
slight imbalance between the ratios of men and women in 
the two groups (Table 1). At baseline, the mean morning 
PEF was 84.9% of predicted in patients receiving once-daily 
treatment, and 89.1% in patients receiving twice-daily treat- 
ment. The mean change from baseline during double-blind 
treatment in the two groups was 4.0 and 3.4%, respectively. 
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The estimated mean difference between the groups was 
- 0.3%, which was not significant (95% confidence limits: 
- 3.3, +2.8%). Thus, the results of this analysis were 
consistent with those of the primary analysis. 
Estimated differences in secondary efficacy variables 
(evening PEF, symptom scores and spirometry data) 
between the two groups are summarized in Table 3. In each 
case, the 95% confidence limits overlapped zero, indicating 
that there were no significant differences between the two 
groups in any of these secondary measures. 
At the end of the double-blind treatment period, 25 
patients (27.8%) in the once-daily treatment group satisfied 
all three criteria for stable asthma (PEF and/or FEV,, 
symptoms, and bronchodilator use), compared with 22 
patients (24.2%) in the twice-daily treatment group. The 
corresponding numbers at the end of the first and second 
open treatment periods were 28 (31.1%) and 23 (25.6%) 
respectively, in the once-daily treatment group, and 29 
(31.9%) and 28 (30.8%), respectively, in the twice-daily 
treatment group. Thus, the proportion of patients with 
stable asthma was similar during each of the three treat- 
ment periods. However, a patient with stable asthma during 
one period did not necessarily show stable asthma during 
the other periods. As a result, it was not possible to 
determine the minimum maintenance dose of budesonide. 
There were no significant differences in morning PEF, 
secondary efficacy variables, or the number of exacer- 
bations between the two groups in either of the two open 
treatment periods. 
TOLERABILITY 
A total of 136 adverse events were reported during the 
double-blind treatment period, of which 50 occurred in 
patients receiving once-daily treatment and 86 in patients 
receiving twice-daily treatment. Adverse events were 
reported by 39% of patients receiving once-daily treatment 
TABLE 3. Changes in secondary efficacy variables from baseline to the end of the double-blind 
treatment phase and estimated differences between treatment effects (once or twice daily) 
Change Change 
(once daily) (twice daily) 
Estimated difference 
(once or twice daily) 
(95% confidence interval) 
Diary variables 
Evening PEF (1 min ~ ‘) 
Cough (daytime) 
Cough (night-time) 
Wheeze (daytime) 
Wheeze (night-time) 
Breathlessness (daytime) 
Breathlessness (night-time) 
&agonist use (puffs day - ‘) 
&agonist use (puffs night ~ ‘) 
Clinical assessments 
PEF (1 min - ‘) 
FEV, (1) 
6.1 6.4 - 0.3 (- 14.4-13.7) 
0.47 0.39 0.08 ( - 0.104.25) 
0.38 0.35 0.04 ( - 0.13-0.21) 
0.25 0.23 0.01 (- 0.13-0.16) 
0.24 0.21 0.03 ( - 0.1 l-0.17) 
0.52 0.55 - 0.03 ( - 0.22-O. 16) 
0.43 0.45 - 0.02 ( - 0.20-O. 16) 
0.46 0.38 0.08 ( - 0.13-0.28) 
0.37 0.23 0.14 ( - 0.0330.30) 
20.5 19.5 1.0 (- 18.5-20.5) 
0.03 0.06 - 0.03 ( - 0.1 l-0.06) 
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and 5 1% of patients in the twice-daily treatment group. The 
spectrum of reported events was similar in both groups. The 
most common were respiratory disorders (primarily rhini- 
tis, respiratory infection and pharyngitis), which occurred 
in 28% of patients in the once-daily treatment group and in 
39% of patients in the twice-daily treatment group. Three 
patients, two in the once-daily treatment group (one 
receiving 400 ,ug once daily and one receiving 100 ,ug once 
daily), and one in the twice-daily treatment group (2OOpg 
twice daily), discontinued treatment because of adverse 
events. 
Two adverse events were regarded as serious. One patient 
receiving once-daily treatment developed a severe respirat- 
ory infection, resulting in the development of status asth- 
maticus; he was withdrawn from the study and hospitalized 
and recovered fully. One patient in the twice-daily treat- 
ment group was withdrawn from the study because of 
intervertebral disc hemiation. Neither of these adverse 
events was regarded as related to study medication. 
None of the non-asthma medications given during the 
study were considered to influence the result of the 
investigation. 
Discussion 
The results of this study show that once-daily treatment 
with budesonide Turbuhaler@, 4OOpg, is as effective as 
twice-daily treatment with a 200,~g dose as first-line 
therapy in patients with mild persistent asthma. A compari- 
son of the difference in treatment effects in the two groups 
indicated no significant difference in effect between the two 
regimens. It was not considered ethical to include a placebo 
group, and hence it was not possible to determine the 
significance of changes in absolute values (i.e. to exclude 
placebo effects and determine a true treatment effect). 
Both budesonide regimens improved lung function and 
reduced symptom scores and bronchodilator use from 
baseline. These findings are consistent with those of a 
previous general practice trial (8) which compared the 
effects of budesonide Turbuhaler@, 4OOpg once daily and 
2OOpg twice daily, and placebo, in patients with mild to 
moderate stable asthma who had not previously been 
treated with inhaled glucocorticosteroids. In that study, all 
treatment were more effective than placebo, and once-daily 
treatment with budesonide in the morning or evening was 
as effective as twice-daily treatment, producing increases in 
PEF of 20-30 1 min - ‘. There were also improvements in 
symptom scores and bronchodilator use in the three groups. 
Similarly, a double-blind general practice study showed 
that once-daily treatment with budesonide Turbuhaler@, 
4OO,ug, was effective in patients with mild asthma who had 
not previously received inhaled glucocorticosteroids (11). 
More recently, once-daily treatment with budesonide 
Turbuhaler@, 20O,~g, has been shown to be as effective as 
twice-daily treatment with 100,~g in improving lung func- 
tion and symptom scores in patients with mild asthma who 
had previously been treated with inhaled steroids in doses 
of 200-5OOpg daily (12). Taken together, therefore, these 
studies suggest that once-daily treatment with budesonide 
’ 
Turbuhaler@ can provide effective asthma control in most 
patients with mild to moderate asthma. 
In addition to effective asthma control, once-daily treat- 
ment with budesonide Turbuhaler@ might offer advantages 
in terms of patient convenience and acceptability, and 
hence possibly enhanced compliance. In a randomized 
comparison of budesonide, 4OOpg once daily or 200,~g 
twice daily, and fluticasone propionate, 200 ,ug twice daily, 
61% of patients expressed a preference for once-daily 
treatment over twice-daily treatment (13) and in a placebo- 
controlled trial of budesonide, 400,~g once daily, 97% of 
patients expressed a preference for once-daily treatment 
(11). 
A secondary objective of this study was to determine the 
minimum maintenance dose of budesonide Turbuhalera 
required to control symptoms. It was not possible to do this 
as, in individual patients, asthma fluctuated from stable to 
unstable and vice versa during the course of the study. This 
reflects variation in the degree and severity of the under- 
lying inflammation with time and between patients. 
Furthermore, the definition of stable asthma used in this 
study was dependent on the patients’ baseline status and 
hence patients with stable asthma may have had differing 
baseline degrees of asthma symptoms. 
Although it was not possible to determine the minimum 
maintenance dose of budesonide Turbuhale@, the results 
during the two open treatment periods showed that there 
was no loss of control following dose reduction to levels as 
low as 1OOpg once daily, and that maintenance of asthma 
control did not depend on whether the initial treatment was 
given once or twice daily. These are important findings, 
since current management guidelines recommend establish- 
ing control with a high initial dose of iGCS, and titrating 
the dose down to the lowest level required to maintain 
control. 
In conclusion, the results of this study show that once- 
daily treatment with budesonide Turbuhaler@ is as effective 
as twice-daily treatment as initial therapy in patients with 
mild persistent asthma, and that the initial dose can be 
reduced to maintenance levels (including 100,~g) without 
loss of asthma control. 
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